Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telacebec - Qurient Co

Next Previous
X
Search
Drug Profile

Telacebec - Qurient Co

Alternative Names: Q-203

Latest Information Update: 15 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qurient Co
  • Class Amides; Anti-inflammatories; Antibacterials; Antituberculars; Imidazoles; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Bacterial growth inhibitors; Electron transport complex III inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Tuberculosis
  • Phase I Buruli ulcer

Most Recent Events

  • 03 Jul 2024 Barwon Health plans the TREAT-BU phase II trial for Buruli-ulcer (PO, Tablet) in July 2024 (NCT06481163)
  • 17 May 2024 Pharmacodynamics data from a preclinical trial in Tuberculosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
  • 03 Feb 2023 Telacebec licensed to Global Alliance for TB Drug Development worldwide (except South Korea, Russia and Commonwealth of Independent States (CIS) countries) for the treatment of Tuberculosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top